| Literature DB >> 9680113 |
T Fukushima1, H Inoue, H Takemura, S Kishi, T Yamauchi, K Inai, T Nakayama, S Imamura, Y Urasaki, T Nakamura, T Ueda.
Abstract
We investigated the cytotoxicity and cellular pharmacology of idarubicin (IDA), idarubicinol (IDAol) and daunorubicin (DNR) in K562/VP-H2 cells, which show topoisomerase II-related multidrug resistance but do not overexpress P-glycoprotein. K562/VP-H2 cells were less resistant to IDA and IDAol than to DNR. There was no significant difference in the accumulation of each drug between K562 and K562/VP-H2 cells. The cleavage of DNA induced by each drug was decreased in K562/VP-H2 cells, however, the decrease in cleavage in K562/VP-H2 cells was less with IDA and IDAol than with DNR. These results suggest that IDA and IDAol have more cytotoxic potency than DNR in topoisomerase II-related multidrug-resistant leukemia cells.Entities:
Mesh：
Substances：
Year: 1998 PMID： 9680113 DOI： 10.1016/s0145-2126(98)00060-5
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156